Back

Dual antiplatelet therapy with 3rd generation P2Y12 inhibitors in STEMI patients: impact of Body Mass Index on high on-treatment platelet reactivity

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Pharmacology and pharmacotherapy e-posters Antiplatelet Drugs ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Fernando Scudiero

Bolognini Hospital, Seriate (Italy)

57 More presentations in this session

Presentation thumbnail
Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials
Doctor J. Borovac (Split, HR)
Abstract Slides
Presentation thumbnail
The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus
Doctor A. KANWAL (Valhalla, US)
Abstract Slides
Presentation thumbnail
Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.
Doctor K. Dzaurova (Moscow, RU)
Abstract Slides
Presentation thumbnail
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
Mrs A. Boulmpou (Nijmegen, NL)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy e-posters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources